Siemens Healthineers launches capillary testing on Atellica analyzers

Key Highlights

  • Supports key assays including metabolic panels, lipid panels, thyroid, Vitamin D, and HbA1c, meeting common laboratory needs.
  • Currently available with four assays in the U.S.: total protein, ALT, AST, and T3, with more claims under review.
  • Aims to expand testing options and improve operational efficiency for laboratories and healthcare providers.

Siemens Healthineers has launched capillary testing on the Atellica CH, IM, and CI Analyzers after receiving CE-mark for 24 capillary blood testing claims1, according to an announcement.

Capillary testing on the Atellica analyzers supports the most common laboratory testing needs – including key assays that comprise the comprehensive metabolic panel, lipid panels, thyroid, Vitamin D, and HbA1c.  Blood collection for capillary testing is mostly done through a finger prick or heel stick, rather than a standard blood draw (venipuncture) where a needle is inserted directly into a vein, offering greater flexibility for diverse patient testing needs.

Siemens Healthineers offers four assays with capillary claims in the United States: total protein (TP_2), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and triiodothyronine (T3). Siemens Healthineers is pursuing additional capillary testing claims with the FDA, subject to regulatory review, as part of its broader strategy to support laboratories in expanding their offerings for patient testing and simplifying their operations1. The latest information can be found here.

1. Not available for sale in the U.S. Future availability cannot be guaranteed.

About the Author

Sign up for our eNewsletters
Get the latest news and updates